{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:14:27Z","timestamp":1789600467864,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.numecd.2025.104124","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T03:00:31Z","timestamp":1746586831000},"page":"104124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipoprotein(a) and aortic stenosis: Practical insights"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-8905","authenticated-orcid":false,"given":"Kyriakos","family":"Dimitriadis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos G.","family":"Kyriakoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pyrpyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Beneki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Kamperidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Kollias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Cenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Aznaouridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Aggeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2025.104124_bib1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jacc.2013.05.015","article-title":"Aortic stenosis in the elderly","volume":"62","author":"Osnabrugge","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib2","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1093\/eurheartj\/ehae466","article-title":"European society of cardiology: the 2023 Atlas of cardiovascular disease statistics","volume":"45","author":"Timmis","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/ATVBAHA.119.313067","article-title":"Aortic valve stenosis","volume":"40","author":"Goody","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2025.104124_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pcad.2023.06.002","article-title":"The common pathobiology between coronary artery disease and calcific aortic stenosis: evidence and clinical implications","volume":"79","author":"Abdul-Rahman","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2025.104124_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients","volume":"380","author":"Mack","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib7","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients","volume":"380","author":"Popma","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib8","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1093\/eurheartj\/ehae331","article-title":"Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial","volume":"45","author":"J\u00f8rgensen","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib9","article-title":"Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis","author":"G\u00e9n\u00e9reux","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease","volume":"7","author":"Duarte","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10654-022-00956-4","article-title":"Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis","volume":"38","author":"Amiri","year":"2023","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.numecd.2025.104124_bib12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2025.104124_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034493","article-title":"Association of lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the mass general brigham lp(a) registry","volume":"13","author":"Shiyovich","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2025.104124_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034774","article-title":"Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the CASABLANCA study","volume":"13","author":"Januzzi","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2025.104124_bib15","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2025.104124_bib16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104124_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28030969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment","volume":"28","author":"Lampsas","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.numecd.2025.104124_bib18","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib19","doi-asserted-by":"crossref","unstructured":"Brown MS, Goldstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature n.d.;330:113\u2013114. https:\/\/doi.org\/10.1038\/330113a0.","DOI":"10.1038\/330113a0"},{"key":"10.1016\/j.numecd.2025.104124_bib20","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2025.104124_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914939","article-title":"Lp(a) in the pathogenesis of aortic stenosis and approach to therapy with Antisense oligonucleotides or short interfering RNA","volume":"24","author":"Di Costanzo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2025.104124_bib23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2021.11.029","article-title":"Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the Copenhagen General Population Study","volume":"349","author":"Kaltoft","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104124_bib24","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","article-title":"Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis","volume":"119","author":"Pantelidis","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.numecd.2025.104124_bib25","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/heartjnl-2016-309404","article-title":"Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults","volume":"102","author":"Bortnick","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2025.104124_bib26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0002-9149(99)80263-X","article-title":"Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study)","volume":"76","author":"Gotoh","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease","volume":"29","author":"Stewart","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.numecd.2025.104124_bib29","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamacardio.2017.4266","article-title":"Association of LPA variants with aortic stenosis","volume":"3","author":"Chen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2019.1581","article-title":"Genetic variation in LPA , calcific aortic valve stenosis in patients undergoing cardiac surgery, and familial risk of aortic valve microcalcification","volume":"4","author":"Perrot","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003271","article-title":"Sex-specific associations of genetically predicted circulating lp(a) (Lipoprotein(a)) and hepatic LPA gene expression levels with cardiovascular outcomes: mendelian randomization and observational analyses","volume":"14","author":"Guertin","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.numecd.2025.104124_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11071823","article-title":"Lipoprotein(a) as a potential predictive factor for earlier aortic valve replacement in patients with bicuspid aortic valve","volume":"11","author":"Krzesi\u0144ska","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.numecd.2025.104124_bib35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijcard.2014.03.206","article-title":"Bicuspid aortic valve disease and lipoprotein(a)--a concept worth exploring?","volume":"174","author":"Ker","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11739-018-1925-8","article-title":"Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study","volume":"14","author":"Sticchi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.numecd.2025.104124_bib37","doi-asserted-by":"crossref","DOI":"10.31083\/j.fbl2802032","article-title":"Molecular linkage under the bicuspid aortic valve with dyslipidemia","volume":"28","author":"Wu","year":"2023","journal-title":"Frontiers in Bioscience - Landmark"},{"key":"10.1016\/j.numecd.2025.104124_bib38","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib39","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib40","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/eurheartj\/ehac377","article-title":"Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification","volume":"43","author":"Kaiser","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.amjcard.2009.10.071","article-title":"Incidence and progression of aortic valve calcium in the multi-ethnic study of atherosclerosis (MESA)","volume":"105","author":"Owens","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis","volume":"9","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib43","article-title":"Association between lipoprotein(a) and calcific aortic valve disease: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.numecd.2025.104124_bib44","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: a systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2025.104124_bib45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2022.01.022","article-title":"Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis","volume":"349","author":"Bhatia","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2025.104124_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0003319719826461","article-title":"Lipoprotein(a) in patients undergoing transcatheter aortic valve replacement","volume":"70","author":"Ma","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.numecd.2025.104124_bib47","article-title":"Lipoprotein(a) levels in severe aortic stenosis referred for transcatheter aortic valve implantation compared to controls","volume":"3","author":"Loewenstein","year":"2024","journal-title":"JACC (J Am Coll Cardiol): Advances"},{"key":"10.1016\/j.numecd.2025.104124_bib48","article-title":"Lipoprotein(a) and high-sensitivity C-reactive protein compound the risk of hypoattenuating leaflet thickening after transcatheter aortic valve replacement","volume":"13","author":"Shi","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2025.104124_bib49","doi-asserted-by":"crossref","DOI":"10.5114\/aic.2024.142403","article-title":"Temporal changes in biomarker levels and their association with the early degeneration stage of transcatheter aortic valves in 18F-fluorodeoxyglucose and 18F-sodium fluoride positron emission tomography studies","author":"Sorysz","year":"2024","journal-title":"Adv Interventional Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ehjci\/jeac274","article-title":"Serum lipoprotein(a) and bioprosthetic aortic valve degeneration","volume":"24","author":"Botezatu","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.numecd.2025.104124_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/heartjnl-2023-322987","article-title":"Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration","volume":"110","author":"Farina","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2025.104124_bib52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacl.2022.12.005","article-title":"Recommended and observed statin use among U.S. Adults - national health and nutrition examination survey, 2011-2018","volume":"17","author":"Thompson-Paul","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2025.104124_bib53","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104124_bib54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jacl.2017.10.001","article-title":"Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk","volume":"12","author":"Arsenault","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2025.104124_bib55","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/heart.89.8.893","article-title":"Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia","volume":"89","author":"van Wissen","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2025.104124_bib56","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105275","article-title":"Effect of different types and dosages of statins on plasma lipoprotein(a) levels: a network meta-analysis","volume":"163","author":"Wang","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.numecd.2025.104124_bib58","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib59","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.numecd.2025.104124_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2025.104124_bib61","doi-asserted-by":"crossref","DOI":"10.1097\/HCO.0000000000001137","article-title":"Effects of bempedoic acid on markers of inflammation and Lp(a)","author":"Reddy","year":"2024","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib62","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib63","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib64","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2025.104124_bib65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib66","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/clc.23607","article-title":"Effectiveness of proprotein convertase subtilisin\/kexin\u20109 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic","volume":"44","author":"Chakraborty","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib67","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.3390\/jcm13175040","article-title":"Proprotein convertase subtilisin\/kexin type 9 inhibitors in patients following acute coronary syndromes: from lipid lowering and plaque stabilization to improved outcomes","volume":"13","author":"Dimitriadis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2025.104124_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","article-title":"The trajectory of lipoprotein(a) during the peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/kexin type 9 inhibition","volume":"171","author":"Vavuranakis","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib69","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jjcc.2020.04.006","article-title":"Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction","volume":"76","author":"Nakamura","year":"2020","journal-title":"J Cardiol"},{"key":"10.1016\/j.numecd.2025.104124_bib70","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib71","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib72","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib73","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2025.104124_bib74","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104124_bib75","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2025.104124_bib76","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib77","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.numecd.2025.104124_bib78","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2025.104124_bib79","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a)","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104124_bib80","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a)","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2025.104124_bib81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.omtm.2022.10.009","article-title":"LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: a proof-of-concept study","volume":"27","author":"Doerfler","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.numecd.2025.104124_bib82","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024870","article-title":"Lipoprotein(a) and subclinical vascular and valvular calcification on cardiac computed tomography: the atherosclerosis risk in communities study","volume":"11","author":"Obisesan","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2025.104124_bib83","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcct.2020.06.002","article-title":"Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: the Multi-Ethnic Study of Atherosclerosis","volume":"15","author":"Garg","year":"2021","journal-title":"J Cardiovasc Comput Tomogr"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325002789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475325002789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:35:47Z","timestamp":1758062147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475325002789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0939475325002789"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104124","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) and aortic stenosis: Practical insights","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2025.104124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104124"}}